|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CA2915412A1
(en)
*
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
PT2968552T
(pt)
|
2013-03-14 |
2020-05-18 |
Scripps Research Inst |
Anticorpo dos agentes alvo, combinações e uso para os mesmos
|
|
EP4067383A1
(en)
|
2013-07-25 |
2022-10-05 |
Cytomx Therapeutics Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
CA2925106C
(en)
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
CN106029696B
(zh)
|
2013-12-17 |
2020-07-28 |
基因泰克公司 |
抗cd3抗体及使用方法
|
|
IL302642B2
(en)
*
|
2014-01-31 |
2025-04-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
MX2017006571A
(es)
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas activadoras de celulas t.
|
|
LT3221357T
(lt)
|
2014-11-20 |
2020-08-25 |
F. Hoffmann-La Roche Ag |
Bendros lengvosios grandinės ir naudojimo būdai
|
|
MA41374A
(fr)
*
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
JP6841754B2
(ja)
*
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
WO2017011580A2
(en)
*
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3352760A4
(en)
|
2015-09-21 |
2019-03-06 |
Aptevo Research and Development LLC |
CD3-BINDING POLYPEPTIDES
|
|
SG10201913746RA
(en)
*
|
2015-11-03 |
2020-03-30 |
Ambrx Inc |
Anti-cd3-folate conjugates and their uses
|
|
FI3377103T4
(fi)
|
2015-11-19 |
2025-04-16 |
Revitope Limited |
Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
ES2992761T3
(en)
*
|
2016-02-04 |
2024-12-17 |
Scripps Research Inst |
Humanized anti-cd3 antibodies, conjugates and uses thereof
|
|
US10745478B2
(en)
*
|
2016-02-19 |
2020-08-18 |
Dignity Health |
Antibody fusion protein and related compositions for targeting cancer
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
RS64266B1
(sr)
|
2016-03-22 |
2023-07-31 |
Hoffmann La Roche |
Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
|
|
EP3433280B1
(en)
*
|
2016-03-22 |
2023-04-19 |
F. Hoffmann-La Roche AG |
Protease-activated t cell bispecific molecules
|
|
ES2906639T3
(es)
|
2016-03-25 |
2022-04-19 |
Biomunex Pharmaceuticals |
Moléculas de unión a CD38 y PD-L1
|
|
AU2017255970B2
(en)
*
|
2016-04-28 |
2024-06-27 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting EGFR and HER2
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CN116903741A
(zh)
|
2016-06-20 |
2023-10-20 |
科马布有限公司 |
特异性结合于pd-l1的抗体或其抗原结合片段及其用途
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
CN109843327B
(zh)
|
2016-07-07 |
2022-05-13 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
AU2017355446A1
(en)
*
|
2016-11-03 |
2019-05-02 |
Bristol-Myers Squibb Company |
Activatable anti-CTLA-4 antibodies and uses thereof
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
AU2017364817B2
(en)
|
2016-11-28 |
2023-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding domain, and polypeptide including conveying section
|
|
MX2019005947A
(es)
|
2016-11-28 |
2019-08-26 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a ligando que tiene actividad de union a ligando ajustable.
|
|
CN110087530A
(zh)
|
2016-12-07 |
2019-08-02 |
普罗根尼蒂公司 |
胃肠道检测方法、装置和系统
|
|
WO2018108759A1
(en)
*
|
2016-12-13 |
2018-06-21 |
F. Hoffmann-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
IL267485B2
(en)
|
2016-12-21 |
2024-01-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies and uses thereof
|
|
WO2018156802A1
(en)
*
|
2017-02-22 |
2018-08-30 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
US10093731B2
(en)
|
2017-02-24 |
2018-10-09 |
Kindred Biosciences, Inc. |
Anti-IL31 antibodies for veterinary use
|
|
IL269559B2
(en)
|
2017-03-27 |
2024-06-01 |
Biomunex Pharmaceuticals |
Stable multispecific antibodies
|
|
EP4108183A1
(en)
|
2017-03-30 |
2022-12-28 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
BR112019020940A2
(pt)
|
2017-04-11 |
2020-05-05 |
Inhibrx, Inc. |
construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
ES3015105T3
(en)
*
|
2017-06-05 |
2025-04-29 |
Numab Therapeutics AG |
Anti-cd3 epsilon antibodies
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN118146370A
(zh)
|
2017-06-20 |
2024-06-07 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
JP7356970B2
(ja)
*
|
2017-06-25 |
2023-10-05 |
システィミューン, インク. |
多重特異性抗体とその作製及び使用方法
|
|
EP3655779A1
(en)
*
|
2017-07-20 |
2020-05-27 |
CytomX Therapeutics, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
EP3676294A4
(en)
*
|
2017-08-28 |
2021-12-22 |
Systimmune, Inc. |
ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
|
|
WO2019042153A1
(zh)
*
|
2017-09-01 |
2019-03-07 |
四川科伦博泰生物医药股份有限公司 |
重组双特异性抗体
|
|
BR112020004543A2
(pt)
|
2017-09-08 |
2020-09-08 |
Maverick Therapeutics, Inc. |
proteínas de ligação ativadas condicionalmente restritas
|
|
EA202090817A1
(ru)
|
2017-10-13 |
2020-09-08 |
Харпун Терапьютикс, Инк. |
Триспецифические белки и способы их применения
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
BR112020007309A2
(pt)
*
|
2017-10-14 |
2020-09-29 |
Cytomx Therapeutics, Inc. |
anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
|
|
KR20200089312A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
KR20250134208A
(ko)
|
2017-11-28 |
2025-09-09 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
|
MX2020006494A
(es)
|
2017-12-22 |
2020-11-24 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22.
|
|
CN107880129B
(zh)
*
|
2017-12-28 |
2021-01-15 |
广州市鲁诚生物科技有限公司 |
一种重组抗体及其制备方法
|
|
WO2019148445A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
EP3752196A4
(en)
*
|
2018-02-15 |
2022-03-23 |
MacroGenics, Inc. |
CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
|
|
EP3769309A1
(en)
|
2018-03-20 |
2021-01-27 |
Cytomx Therapeutics Inc. |
Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
|
|
CN110305217B
(zh)
*
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
|
IL323061A
(en)
|
2018-04-11 |
2025-10-01 |
Inhibrx Biosciences Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
EP3788077A1
(en)
|
2018-05-02 |
2021-03-10 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
IL278615B1
(en)
|
2018-05-14 |
2025-10-01 |
Werewolf Therapeutics Inc |
Activatable interleukin 12 polypeptides and methods of using them
|
|
ES2955511T3
(es)
|
2018-05-14 |
2023-12-04 |
Werewolf Therapeutics Inc |
Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
|
|
US20210230599A1
(en)
*
|
2018-05-15 |
2021-07-29 |
Vitrisa Therapeutics, Inc. |
Stem-loop compositions and methods for inhibiting interleukin-8
|
|
TWI793325B
(zh)
*
|
2018-05-23 |
2023-02-21 |
美商輝瑞大藥廠 |
對cd3具特異性之抗體及其用途
|
|
WO2019230867A1
(en)
|
2018-05-30 |
2019-12-05 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising aggrecan binding domain and carrying moiety
|
|
US20210253672A1
(en)
|
2018-05-30 |
2021-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule containing single domain antibody
|
|
WO2019232323A1
(en)
*
|
2018-05-31 |
2019-12-05 |
Board Of Regents, The University Of Texas System |
Bi-specific antibodies and use thereof
|
|
TWI848953B
(zh)
*
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
CA3103414A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Bioatla, Inc. |
Multi-specific antibody constructs
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12129298B2
(en)
|
2018-06-21 |
2024-10-29 |
Daiichi Sankyo Company, Limited |
Compositions including CD3 antigen binding fragments and uses thereof
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
KR20210039395A
(ko)
|
2018-07-31 |
2021-04-09 |
암젠 인크 |
마스킹된 항체의 약제학적 제형
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
JP7453219B2
(ja)
|
2018-10-11 |
2024-03-19 |
インヒブリックス, インコーポレイテッド |
Pd-1単一ドメイン抗体およびその治療用組成物
|
|
CN113166263A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
Dll3单域抗体及其治疗性组合物
|
|
WO2020076970A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
CA3114693A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
CN116726362A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
AU2019394972A1
(en)
|
2018-12-06 |
2021-06-03 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
CN116178547A
(zh)
*
|
2019-02-22 |
2023-05-30 |
武汉友芝友生物制药股份有限公司 |
Cd3抗原结合片段及其应用
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
AU2020252556A1
(en)
|
2019-04-05 |
2021-10-21 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
|
CN113811546B
(zh)
*
|
2019-05-07 |
2025-03-11 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
KR102878895B1
(ko)
|
2019-05-21 |
2025-10-31 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
|
WO2020246563A1
(ja)
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
抗体切断部位結合分子
|
|
CN114423499A
(zh)
*
|
2019-06-06 |
2022-04-29 |
佳努克斯治疗公司 |
与肿瘤激活的t细胞衔接子相关的组合物和方法
|
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
CA3143519A1
(en)
*
|
2019-06-26 |
2020-12-30 |
Volker Schellenberger |
Cd3 antigen binding fragments and compositions comprising same
|
|
TWI809286B
(zh)
|
2019-07-05 |
2023-07-21 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
|
GB201912681D0
(en)
*
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
CN114786776A
(zh)
|
2019-09-18 |
2022-07-22 |
拉姆卡普生物阿尔法股份公司 |
针对ceacam5和cd3的双特异性抗体
|
|
JP2022548310A
(ja)
*
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
|
|
TW202132352A
(zh)
*
|
2019-11-06 |
2021-09-01 |
美商西雅圖免疫公司 |
導引和導航控制蛋白及其製造和使用方法
|
|
EP4058471A1
(en)
|
2019-11-14 |
2022-09-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
EP4090686A4
(en)
*
|
2020-01-17 |
2024-03-27 |
Immune Targeting Inc. |
PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
|
|
KR20220148175A
(ko)
|
2020-01-29 |
2022-11-04 |
인히브릭스, 인크. |
Cd28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
|
|
TWI888487B
(zh)
*
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
|
EP4114373A4
(en)
*
|
2020-03-03 |
2024-05-01 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
JP2024518539A
(ja)
*
|
2020-04-04 |
2024-05-01 |
ジャナックス セラピューティクス,インク. |
抗体を標的とする腫瘍によって活性化されるegfrおよびエフェクター細胞抗原に関する組成物および方法
|
|
EP4132656A1
(en)
|
2020-04-09 |
2023-02-15 |
CytomX Therapeutics, Inc. |
Compositions containing activatable antibodies
|
|
BR112022021690A2
(pt)
|
2020-04-29 |
2022-12-20 |
Teneobio Inc |
Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
|
|
KR20230005952A
(ko)
*
|
2020-05-04 |
2023-01-10 |
임뮤노라이즌 엘티디. |
전구체 삼중-특이적 항체 구조체 및 그의 이용 방법
|
|
CN116348597A
(zh)
|
2020-08-11 |
2023-06-27 |
佳努克斯治疗公司 |
可切割性接头组合物和方法
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
US20240092931A1
(en)
*
|
2020-08-24 |
2024-03-21 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
|
BR112023003366A2
(pt)
|
2020-08-25 |
2023-05-09 |
Gilead Sciences Inc |
Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
|
|
US12116411B2
(en)
*
|
2020-11-03 |
2024-10-15 |
Abzyme Therapeutics Llc |
Antibodies binding to human CD3 at acidic pH
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体の皮下投薬
|
|
US20240010748A1
(en)
*
|
2020-11-10 |
2024-01-11 |
Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. |
Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
|
|
WO2022115865A2
(en)
*
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
EP4259177A4
(en)
*
|
2020-12-08 |
2024-11-06 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
EP4259193A4
(en)
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
KR102671734B1
(ko)
*
|
2021-04-13 |
2024-06-04 |
건국대학교 글로컬산학협력단 |
개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
CA3218578A1
(en)
|
2021-05-14 |
2022-11-17 |
Carol Elaine O'hear |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
WO2022266341A1
(en)
*
|
2021-06-16 |
2022-12-22 |
Regents Of The University Of Minnesota |
Targeted adam17 blocker compounds, anti-adam17 antibodies, methods of making, and methods of using
|
|
WO2022272033A2
(en)
*
|
2021-06-25 |
2022-12-29 |
Harpoon Therapeutics, Inc. |
Extended-release immune cell engaging proteins and methods of treatment
|
|
US20240309099A1
(en)
*
|
2021-08-25 |
2024-09-19 |
Systimmune, Inc. |
Bispecific tetravalent antibody targeting egfr and her3
|
|
CN115894701A
(zh)
*
|
2021-09-30 |
2023-04-04 |
上海君实生物医药科技股份有限公司 |
结合cd3的抗体及其用途
|
|
TW202323282A
(zh)
|
2021-10-15 |
2023-06-16 |
美商賽特艾克斯生物製藥公司 |
可活化之多肽複合物
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
MX2024004563A
(es)
|
2021-10-15 |
2024-04-30 |
Cytomx Therapeutics Inc |
Complejo polipeptidico activable.
|
|
AU2022401024A1
(en)
|
2021-11-30 |
2024-05-16 |
Daiichi Sankyo Company, Limited |
Protease-cleavable masked antibodies
|
|
US20240409662A1
(en)
*
|
2021-12-09 |
2024-12-12 |
Vibrant Pharma Limited |
Antibody masks and uses thereof
|
|
US12269887B2
(en)
|
2022-01-20 |
2025-04-08 |
Regents Of The University Of Minnesota |
Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
|
|
EP4477674A1
(en)
|
2022-02-09 |
2024-12-18 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
CN119072488A
(zh)
|
2022-02-23 |
2024-12-03 |
明峰治疗股份公司 |
可活化il-18多肽
|
|
IL314993A
(en)
|
2022-02-23 |
2024-10-01 |
Xencor Inc |
Anti-cd28 x anti-psma antibodies
|
|
US20250333539A1
(en)
|
2022-03-23 |
2025-10-30 |
Cytomx Therapeutics, Inc. |
Activatable antigen-binding protein constructs and uses of the same
|
|
KR20240164782A
(ko)
|
2022-03-23 |
2024-11-20 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
|
|
EP4499685A1
(en)
|
2022-03-25 |
2025-02-05 |
CytomX Therapeutics, Inc. |
Activatable dual-anchored masked molecules and methods of use thereof
|
|
CN119278215A
(zh)
|
2022-04-01 |
2025-01-07 |
西托姆克斯治疗公司 |
Cd3结合蛋白和其使用方法
|
|
CN119300859A
(zh)
|
2022-04-01 |
2025-01-10 |
西托姆克斯治疗公司 |
可激活多特异性分子和其使用方法
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
AR130079A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Restos escindibles por proteasas, y métodos de uso de los mismos
|
|
EP4565690A1
(en)
|
2022-08-01 |
2025-06-11 |
CytomX Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
AR130077A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Substratos escindibles por proteasas, y métodos de uso de los mismos
|
|
TW202426637A
(zh)
|
2022-08-01 |
2024-07-01 |
美商Cytomx生物製藥公司 |
蛋白酶可切割受質及其使用方法
|
|
TW202424184A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Cytomx生物製藥公司 |
蛋白酶可切割部分及其使用方法
|
|
GB202214132D0
(en)
*
|
2022-09-27 |
2022-11-09 |
Coding Bio Ltd |
CLL1 binding molecules
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
CN120435318A
(zh)
*
|
2022-11-10 |
2025-08-05 |
佳努克斯治疗公司 |
靶向egfr和cd3的抗体及其用途
|
|
US20240417436A1
(en)
|
2023-01-11 |
2024-12-19 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
CN120958015A
(zh)
|
2023-04-12 |
2025-11-14 |
西托姆克斯治疗公司 |
掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
CN120936384A
(zh)
|
2023-04-12 |
2025-11-11 |
西托姆克斯治疗公司 |
掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
|
|
KR20250169628A
(ko)
|
2023-04-17 |
2025-12-03 |
시나픽스 비.브이. |
절단 가능한 면역 세포 인게이저
|
|
WO2024243093A2
(en)
*
|
2023-05-19 |
2024-11-28 |
The Regents Of The University Of California |
Multispecific antibodies targeting cd3 and cd22
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
US20250197467A1
(en)
|
2023-08-23 |
2025-06-19 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
WO2025077737A1
(en)
*
|
2023-10-11 |
2025-04-17 |
Biomap (Suzhou) Intelligent Technology Limited |
An anti-cd3 activable antibody and the use thereof
|
|
WO2025201240A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
|
|
WO2025230233A1
(ko)
*
|
2024-05-03 |
2025-11-06 |
국민대학교산학협력단 |
인간 cd3에 특이적인 항체 및 이의 용도
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|